Abbott Avoids Compliance Requirements In Kos Off-Label Marketing Settlement
Executive Summary
A $41 million settlement of kickback and off-label marketing allegations involving Kos Pharmaceuticals’ cholesterol drugs will not result in new compliance requirements for parent company, Abbott Laboratories.
You may also be interested in...
The Era Of Billion Dollar Pharma Settlements
Abbott Laboratories is the third pharmaceutical company to reach a settlement with the Department of Justice in excess of $1 billion. A look at the deals struck since Eli Lilly began the billion dollar club in 2009 shows the activities the government is investigating and the level of liability that companies face.
AWP Litigation: Three More Companies Ink Deals With DoJ; Roxane Sets A Record
The heavy docket of average wholesale price cases got a bit lighter as three pharma companies agreed to pay $421 million to settle claims they inflated the AWP of numerous drugs, thus increasing reimbursement levels.
AWP Litigation: Three More Companies Ink Deals With DoJ; Roxane Sets A Record
The heavy docket of average wholesale price cases got a bit lighter as three pharma companies agreed to pay $421 million to settle claims they inflated the AWP of numerous drugs, thus increasing reimbursement levels.